Catatonic schizophrenia: therapeutic challenges and potentially a new role for electroconvulsive therapy?
- PMID: 23897375
- PMCID: PMC3736193
- DOI: 10.1136/bcr-2013-009153
Catatonic schizophrenia: therapeutic challenges and potentially a new role for electroconvulsive therapy?
Abstract
A 36-year-old man with known schizophrenia, presented with increasingly bizarre behaviour. The development of catatonia and subsequent neuroleptic malignant syndrome in itself posed numerous therapeutic challenges. However, following resolution of neuroleptic malignant syndrome, the reintroduction of antipsychotics was not tolerated. This case report proposes a novel use for electroconvulsive therapy as a treatment of mental state, following resolution of neuroleptic malignant syndrome, to facilitate successful reintroduction of antipsychotics.
Similar articles
-
[The application of electroconvulsive therapy in neuroleptic malignant syndrome treatment in patient with catatonic schizophrenia].Wiad Lek. 2005;58(9-10):572-4. Wiad Lek. 2005. PMID: 16529073 Polish.
-
[Catatonia and neuroleptic malignant syndrome in view of a psychopathological and pathophysiological overlap: a brief review].Neuropsychopharmacol Hung. 2014 Mar;16(1):19-28. Neuropsychopharmacol Hung. 2014. PMID: 24687015 Review. Hungarian.
-
[Catatonia, malignant neuroleptic syndrome and myositis ossificans].Nervenarzt. 1996 May;67(5):413-7. Nervenarzt. 1996. PMID: 9005354 German.
-
Neuroleptic malignant syndrome and psychotic illness.Br J Psychiatry. 1989 Dec;155:852-4. doi: 10.1192/bjp.155.6.852. Br J Psychiatry. 1989. PMID: 2575922
-
Catatonia and its treatment.Schizophr Bull. 2010 Mar;36(2):239-42. doi: 10.1093/schbul/sbp141. Epub 2009 Dec 7. Schizophr Bull. 2010. PMID: 19969591 Free PMC article. Review.
References
-
- Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;2013:1715–36 - PubMed
-
- Chakraborty N, Johnston T. Aripiprazole and neuroleptic malignant syndrome. Int Clin Psychopharmacol 2004;2013:351–3 - PubMed
-
- Mizuno Y, Takubo H. Malignant syndrome in Parkinson's disease: concept and review of the literature. Parkinsonism Relat Disord 2003;2013(Suppl 1):S3–9 - PubMed
-
- Vesperini S, Papetti F. Are catatonia and neuroleptic malignant syndrome related conditions? Encephale 2010;2013:105–10 - PubMed
-
- Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 1999;2013:169–80 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources